Ignite Creation Date:
2025-12-24 @ 11:52 PM
Ignite Modification Date:
2026-05-15 @ 3:49 PM
Study NCT ID:
NCT02227251
Status:
RECRUITING
Last Update Posted:
2025-10-01
First Post:
2014-08-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Sponsor:
Karyopharm Therapeutics Inc
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
KCP-330-009
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None